{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:53:18Z","timestamp":1794477198753,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02360-z","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T10:01:31Z","timestamp":1712138491000},"page":"1839-1850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Asprosin: its function as a novel endocrine factor in metabolic-related diseases"],"prefix":"10.1007","volume":"47","author":[{"given":"Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8382-5328","authenticated-orcid":false,"given":"S.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"3","key":"2360_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165(3):566\u2013579. https:\/\/doi.org\/10.1016\/j.cell.2016.02.063","journal-title":"Cell"},{"issue":"2","key":"2360_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/nu13020620","volume":"13","author":"AI Mazur-Bialy","year":"2021","unstructured":"Mazur-Bialy AI (2021) Asprosin\u2014a fasting-induced, glucogenic, and orexigenic adipokine as a new promising player will it be a new factor in the treatment of obesity, diabetes, or infertility? A review of the literature. Nutrients 13(2):620. https:\/\/doi.org\/10.3390\/nu13020620","journal-title":"Nutrients"},{"key":"2360_CR3","doi-asserted-by":"publisher","first-page":"1101091","DOI":"10.3389\/fendo.2022.1101091","volume":"13","author":"M Farrag","year":"2022","unstructured":"Farrag M, Ait Eldjoudi D, Gonzalez-Rodriguez M, Cordero-Barreal A, Ruiz-Fernandez C, Capuozzo M et al (2022) Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol (Lausanne) 13:1101091. https:\/\/doi.org\/10.3389\/fendo.2022.1101091","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2360_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00564-w","author":"S Naiemian","year":"2020","unstructured":"Naiemian S, Naeemipour M, Zarei M, Lari Najafi M, Gohari A, Behroozikhah MR et al (2020) Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. https:\/\/doi.org\/10.1186\/s13098-020-00564-w","journal-title":"Diabetol Metab Syndr"},{"key":"2360_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen C, Zhou N, Fu Y, Cheng X (2019) Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 489:183\u2013188. https:\/\/doi.org\/10.1016\/j.cca.2017.10.034","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2360_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13098-021-00668-x","volume":"13","author":"R Wang","year":"2021","unstructured":"Wang R, Lin P, Sun H, Hu W (2021) Increased serum asprosin is correlated with diabetic nephropathy. Diabetol Metab Syndr 13(1):51. https:\/\/doi.org\/10.1186\/s13098-021-00668-x","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"2360_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108614","volume":"37","author":"H Diao","year":"2023","unstructured":"Diao H, Li X, Xu Y, Xing X, Pang S (2023) Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus. J Diabet Complicat 37(11):108614. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108614","journal-title":"J Diabet Complicat"},{"issue":"12","key":"2360_CR8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C et al (2017) Asprosin is a centrally acting orexigenic hormone. Nat Med 23(12):1444\u20131453. https:\/\/doi.org\/10.1038\/nm.4432","journal-title":"Nat Med"},{"issue":"1","key":"2360_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40519-020-00845-3","volume":"26","author":"Y Hu","year":"2021","unstructured":"Hu Y, Xu Y, Zheng Y, Kang Q, Lou Z, Liu Q et al (2021) Increased plasma asprosin levels in patients with drug-naive anorexia nervosa. Eat Weight Disord 26(1):313\u2013321. https:\/\/doi.org\/10.1007\/s40519-020-00845-3","journal-title":"Eat Weight Disord"},{"issue":"8","key":"2360_CR10","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/oby.23471","volume":"30","author":"H Cantay","year":"2022","unstructured":"Cantay H, Binnetoglu K, Gul HF, Bingol SA (2022) Investigation of serum and adipose tissue levels of asprosin in patients with severe obesity undergoing sleeve gastrectomy. Obesity 30(8):1639\u20131646. https:\/\/doi.org\/10.1002\/oby.23471","journal-title":"Obesity"},{"issue":"5","key":"2360_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41366-018-0248-1","volume":"43","author":"CY Wang","year":"2019","unstructured":"Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC et al (2019) Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes 43(5):1019\u20131025. https:\/\/doi.org\/10.1038\/s41366-018-0248-1","journal-title":"Int J Obes"},{"key":"2360_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091428","author":"M Wiecek","year":"2019","unstructured":"Wiecek M, Szymura J, Sproull J, Szygula Z (2019) Decreased blood asprosin in hyperglycemic menopausal women as a result of whole-body cryotherapy regardless of metabolic syndrome. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8091428","journal-title":"J Clin Med"},{"issue":"1","key":"2360_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5603\/EP.a2020.0059","volume":"72","author":"N Gozel","year":"2021","unstructured":"Gozel N, Kilinc F (2021) Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol 72(1):37\u201343. https:\/\/doi.org\/10.5603\/EP.a2020.0059","journal-title":"Endokrynol Pol"},{"issue":"4","key":"2360_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000500523","volume":"91","author":"W Long","year":"2019","unstructured":"Long W, Xie X, Du C, Zhao Y, Zhang C, Zhan D et al (2019) Decreased circulating levels of asprosin in obese children. Horm Res Paediatr 91(4):271\u2013277. https:\/\/doi.org\/10.1159\/000500523","journal-title":"Horm Res Paediatr"},{"key":"2360_CR15","doi-asserted-by":"publisher","first-page":"155477","DOI":"10.1016\/j.cyto.2021.155477","volume":"142","author":"D Corica","year":"2021","unstructured":"Corica D, Aversa T, Curr\u00f2 M, Tropeano A, Pepe G, Alibrandi A et al (2021) Asprosin serum levels and glucose homeostasis in children with obesity. Cytokine 142:155477. https:\/\/doi.org\/10.1016\/j.cyto.2021.155477","journal-title":"Cytokine"},{"issue":"4","key":"2360_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ped.14176","volume":"62","author":"E Sunnetci Silistre","year":"2020","unstructured":"Sunnetci Silistre E, Hatipogl HU (2020) Increased serum circulating asprosin levels in children with obesity. Pediatr Int 62(4):467\u2013476. https:\/\/doi.org\/10.1111\/ped.14176","journal-title":"Pediatr Int"},{"issue":"4","key":"2360_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000503808","volume":"75","author":"M Wang","year":"2019","unstructured":"Wang M, Yin C, Wang L, Liu Y, Li H, Li M et al (2019) Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab 75(4):205\u2013212. https:\/\/doi.org\/10.1159\/000503808","journal-title":"Ann Nutr Metab"},{"key":"2360_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cytogfr.2021.05.002","volume":"60","author":"K Shabir","year":"2021","unstructured":"Shabir K, Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM et al (2021) Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: comprehensive review of preclinical and clinical evidence. Cytokine Growth Factor Rev 60:120\u2013132. https:\/\/doi.org\/10.1016\/j.cytogfr.2021.05.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2360_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2021.1894178","author":"MG Hekim","year":"2021","unstructured":"Hekim MG, Kelestemur MM, Bulmus FG, Bilgin B, Bulut F, Gokdere E et al (2021) Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch Physiol Biochem. https:\/\/doi.org\/10.1080\/13813455.2021.1894178","journal-title":"Arch Physiol Biochem"},{"key":"2360_CR20","doi-asserted-by":"publisher","first-page":"155184","DOI":"10.1016\/j.cyto.2020.155184","volume":"134","author":"F Ke","year":"2020","unstructured":"Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M et al (2020) Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine 134:155184. https:\/\/doi.org\/10.1016\/j.cyto.2020.155184","journal-title":"Cytokine"},{"issue":"1","key":"2360_CR21","doi-asserted-by":"publisher","first-page":"106979","DOI":"10.1016\/j.ymgme.2022.106979","volume":"138","author":"KM Summers","year":"2023","unstructured":"Summers KM, Bush SJ, Davis MR, Hume DA, Keshvari S, West JA (2023) Fibrillin-1 and asprosin, novel players in metabolic syndrome. Mol Genet Metab 138(1):106979. https:\/\/doi.org\/10.1016\/j.ymgme.2022.106979","journal-title":"Mol Genet Metab"},{"key":"2360_CR22","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.plipres.2023.101240","volume":"91","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhu L, Wang Z, Hua N, Hu S, Chen Y (2023) Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? State Art Rev Prog Lipid Res 91:101240. https:\/\/doi.org\/10.1016\/j.plipres.2023.101240","journal-title":"State Art Rev Prog Lipid Res"},{"key":"2360_CR23","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63784","author":"I Mishra","year":"2021","unstructured":"Mishra I, Duerrschmid C, Ku Z, He Y, Xie W, Silva ES et al (2021) Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. https:\/\/doi.org\/10.7554\/eLife.63784","journal-title":"Elife"},{"issue":"1","key":"2360_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.gene.2016.07.033","volume":"591","author":"LY Sakai","year":"2016","unstructured":"Sakai LY, Keene DR, Renard M, De Backer J (2016) FBN1: the disease-causing gene for marfan syndrome and other genetic disorders. Gene 591(1):279\u2013291. https:\/\/doi.org\/10.1016\/j.gene.2016.07.033","journal-title":"Gene"},{"issue":"5","key":"2360_CR25","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1172\/JCI117930","volume":"95","author":"DM Milewicz","year":"1995","unstructured":"Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T (1995) A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 95(5):2373\u20132378. https:\/\/doi.org\/10.1172\/JCI117930","journal-title":"J Clin Invest"},{"issue":"3","key":"2360_CR26","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1074\/jbc.275.3.2205","volume":"275","author":"DP Reinhardt","year":"2000","unstructured":"Reinhardt DP, Gambee JE, Ono RN, Bachinger HP, Sakai LY (2000) Initial steps in assembly of microfibrils formation of disulfide-cross-linked multimers containing fibrillin-1. J Biol Chem 275(3):2205\u20132210. https:\/\/doi.org\/10.1074\/jbc.275.3.2205","journal-title":"J Biol Chem"},{"issue":"28","key":"2360_CR27","doi-asserted-by":"publisher","first-page":"10155","DOI":"10.1073\/pnas.1401697111","volume":"111","author":"SA Jensen","year":"2014","unstructured":"Jensen SA, Aspinall G, Handford PA (2014) C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43. Proc Natl Acad Sci U S A 111(28):10155\u201310160. https:\/\/doi.org\/10.1073\/pnas.1401697111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2360_CR28","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/hmg\/7.13.2039","volume":"7","author":"L Lonnqvist","year":"1998","unstructured":"Lonnqvist L, Reinhardt D, Sakai L, Peltonen L (1998) Evidence for furin-type activity-mediated C-terminal processing of profibrillin-1 and interference in the processing by certain mutations. Hum Mol Genet 7(13):2039\u20132044. https:\/\/doi.org\/10.1093\/hmg\/7.13.2039","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2360_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.str.2004.02.023","volume":"12","author":"SS Lee","year":"2004","unstructured":"Lee SS, Knott V, Jovanovic J, Harlos K, Grimes JM, Choulier L et al (2004) Structure of the integrin binding fragment from fibrillin-1 gives new insights into microfibril organization. Structure 12(4):717\u2013729. https:\/\/doi.org\/10.1016\/j.str.2004.02.023","journal-title":"Structure"},{"issue":"20","key":"2360_CR30","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1001\/archinte.161.20.2447","volume":"161","author":"B Loeys","year":"2001","unstructured":"Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A (2001) Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 161(20):2447\u20132454. https:\/\/doi.org\/10.1001\/archinte.161.20.2447","journal-title":"Arch Intern Med"},{"key":"2360_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000488","author":"BL Loeys","year":"2010","unstructured":"Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V et al (2010) Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3000488","journal-title":"Sci Transl Med"},{"issue":"5","key":"2360_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/ajmg.a.36449","volume":"164A","author":"A Garg","year":"2014","unstructured":"Garg A, Xing C (2014) De novo heterozygous FBN1 mutations in the extreme C-terminal region cause progeroid fibrillinopathy. Am J Med Genet A 164A(5):1341\u20131345. https:\/\/doi.org\/10.1002\/ajmg.a.36449","journal-title":"Am J Med Genet A"},{"issue":"9","key":"2360_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ejhg.2016.6","volume":"24","author":"E Passarge","year":"2016","unstructured":"Passarge E, Robinson PN, Graul-Neumann LM (2016) Marfanoid-progeroid-lipodystrophy syndrome: a newly recognized fibrillinopathy. Eur J Hum Genet 24(9):1244\u20131247. https:\/\/doi.org\/10.1038\/ejhg.2016.6","journal-title":"Eur J Hum Genet"},{"key":"2360_CR34","doi-asserted-by":"publisher","first-page":"109737","DOI":"10.1016\/j.enzmictec.2020.109737","volume":"144","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhu Z, Zhai W, Bi Y, Yin Y, Zhang W (2021) Expression and purification of asprosin in Pichia pastoris and investigation of its increase glucose uptake activity in skeletal muscle through activation of AMPK. Enzyme Microb Technol 144:109737. https:\/\/doi.org\/10.1016\/j.enzmictec.2020.109737","journal-title":"Enzyme Microb Technol"},{"issue":"2","key":"2360_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J et al (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom 13(2):397\u2013406. https:\/\/doi.org\/10.1074\/mcp.M113.035600","journal-title":"Mol Cell Proteom"},{"issue":"3","key":"2360_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3892\/ol.2021.12911","volume":"22","author":"R Kerslake","year":"2021","unstructured":"Kerslake R, Hall M, Vagnarelli P, Jeyaneethi J, Randeva HS, Pados G et al (2021) A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncol Lett 22(3):650. https:\/\/doi.org\/10.3892\/ol.2021.12911","journal-title":"Oncol Lett"},{"key":"2360_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","volume":"486","author":"T Lee","year":"2019","unstructured":"Lee T, Yun S, Jeong JH, Jung TW (2019) Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation. Mol Cell Endocrinol 486:96\u2013104. https:\/\/doi.org\/10.1016\/j.mce.2019.03.001","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2360_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cmet.2019.05.022","volume":"30","author":"E Li","year":"2019","unstructured":"Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y et al (2019) OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab 30(2):319\u201328 e8. https:\/\/doi.org\/10.1016\/j.cmet.2019.05.022","journal-title":"Cell Metab"},{"issue":"9","key":"2360_CR39","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.4049\/jimmunol.1501734","volume":"196","author":"M Tatematsu","year":"2016","unstructured":"Tatematsu M, Yoshida R, Morioka Y, Ishii N, Funami K, Watanabe A et al (2016) Raftlin controls lipopolysaccharide-induced TLR4 internalization and TICAM-1 signaling in a cell type-specific manner. J Immunol 196(9):3865\u20133876. https:\/\/doi.org\/10.4049\/jimmunol.1501734","journal-title":"J Immunol"},{"issue":"24","key":"2360_CR40","doi-asserted-by":"publisher","first-page":"21129","DOI":"10.1074\/jbc.M009164200","volume":"276","author":"J da Silva Correia","year":"2001","unstructured":"da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ (2001) Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex transfer from CD14 to TLR4 and MD-2. J Biol Chem 276(24):21129\u201321135. https:\/\/doi.org\/10.1074\/jbc.M009164200","journal-title":"J Biol Chem"},{"key":"2360_CR41","doi-asserted-by":"publisher","first-page":"2521096","DOI":"10.1155\/2019\/2521096","volume":"2019","author":"K Ugur","year":"2019","unstructured":"Ugur K, Aydin S (2019) Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol 2019:2521096. https:\/\/doi.org\/10.1155\/2019\/2521096","journal-title":"Int J Endocrinol"},{"issue":"3","key":"2360_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09513590.2018.1512967","volume":"35","author":"M Alan","year":"2019","unstructured":"Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I et al (2019) Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 35(3):220\u2013223. https:\/\/doi.org\/10.1080\/09513590.2018.1512967","journal-title":"Gynecol Endocrinol"},{"key":"2360_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/j.pbj.0000000000000108","author":"C Luis","year":"2020","unstructured":"Luis C, Fernandes R, Soares R, von Hafe P (2020) A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomed J. https:\/\/doi.org\/10.1097\/j.pbj.0000000000000108","journal-title":"Porto Biomed J"},{"issue":"9","key":"2360_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41574-019-0230-6","volume":"15","author":"L Scheja","year":"2019","unstructured":"Scheja L, Heeren J (2019) The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol 15(9):507\u2013524. https:\/\/doi.org\/10.1038\/s41574-019-0230-6","journal-title":"Nat Rev Endocrinol"},{"key":"2360_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6622129","volume":"2021","author":"T Hong","year":"2021","unstructured":"Hong T, Li J-Y, Wang Y-D, Qi X-Y, Liao Z-Z, Bhadel P et al (2021) High serum asprosin levels are associated with presence of metabolic syndrome. Int J Endocrinol 2021:1\u20137. https:\/\/doi.org\/10.1155\/2021\/6622129","journal-title":"Int J Endocrinol"},{"issue":"8","key":"2360_CR46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1080\/07420528.2020.1792482","volume":"37","author":"HI Ceylan","year":"2020","unstructured":"Ceylan HI, Saygin O, Ozel TU (2020) Assessment of acute aerobic exercise in the morning versus evening on asprosin, spexin, lipocalin-2, and insulin level in overweight\/obese versus normal weight adult men. Chronobiol Int 37(8):1252\u20131268. https:\/\/doi.org\/10.1080\/07420528.2020.1792482","journal-title":"Chronobiol Int"},{"key":"2360_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061568","author":"M Mirr","year":"2023","unstructured":"Mirr M, Braszak-Cymerman A, Ludziejewska A, Kregielska-Narozna M, Bogdanski P, Bryl W et al (2023) Serum asprosin correlates with indirect insulin resistance indices. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11061568","journal-title":"Biomedicines"},{"issue":"13","key":"2360_CR48","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ajmg.a.31840","volume":"143A","author":"B O'Neill","year":"2007","unstructured":"O\u2019Neill B, Simha V, Kotha V, Garg A (2007) Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. Am J Med Genet A 143A(13):1421\u20131430. https:\/\/doi.org\/10.1002\/ajmg.a.31840","journal-title":"Am J Med Genet A"},{"key":"2360_CR49","doi-asserted-by":"publisher","DOI":"10.1530\/joe-20-0503","author":"Y Miao","year":"2021","unstructured":"Miao Y, Qin H, Zhong Y, Huang K, Rao C (2021) Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue. J Endocrinol. https:\/\/doi.org\/10.1530\/joe-20-0503","journal-title":"J Endocrinol"},{"key":"2360_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416166","author":"T Yin","year":"2022","unstructured":"Yin T, Chen S, Zeng G, Yuan W, Lu Y, Zhang Y et al (2022) Angiogenesis-browning interplay mediated by asprosin-knockout contributes to weight loss in mice with obesity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232416166","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2360_CR51","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai T, Autieri MV, Scalia R (2021) Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 320(3):C375\u2013C391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"2360_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065745","author":"AI Mazur-Bialy","year":"2023","unstructured":"Mazur-Bialy AI (2023) Asprosin enhances cytokine production by a Co-culture of fully differentiated mature adipocytes and macrophages leading to the exacerbation of the condition typical of obesity-related inflammation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065745","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2360_CR53","doi-asserted-by":"publisher","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","volume":"27","author":"E Trefts","year":"2017","unstructured":"Trefts E, Gannon M, Wasserman DH (2017) The liver. Curr Biol 27(21):R1147\u2013R1151. https:\/\/doi.org\/10.1016\/j.cub.2017.09.019","journal-title":"Curr Biol"},{"issue":"4","key":"2360_CR54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s12519-021-00444-x","volume":"17","author":"LJ Liu","year":"2021","unstructured":"Liu LJ, Kang YR, Xiao YF (2021) Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity. World J Pediatr 17(4):394\u2013399. https:\/\/doi.org\/10.1007\/s12519-021-00444-x","journal-title":"World J Pediatr"},{"key":"2360_CR55","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.diabres.2023.110642","volume":"199","author":"GN Ertuna","year":"2023","unstructured":"Ertuna GN, Sahiner ES, Yilmaz FM, Ates I (2023) The role of irisin and asprosin level in the pathophysiology of prediabetes. Diabetes Res Clin Pract 199:110642. https:\/\/doi.org\/10.1016\/j.diabres.2023.110642","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2360_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1055\/a-2033-6109","volume":"55","author":"IS Nedeva","year":"2023","unstructured":"Nedeva IS, Assyov Y, Karamfilova V, Vodenicharov V, Gerganova A, Hristova J et al (2023) Circulating asprosin concentrations in patients with obesity and carbohydrate disturbances. Horm Metab Res 55(4):284\u2013289. https:\/\/doi.org\/10.1055\/a-2033-6109","journal-title":"Horm Metab Res"},{"key":"2360_CR57","doi-asserted-by":"publisher","first-page":"9471583","DOI":"10.1155\/2018\/9471583","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y et al (2018) Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm 2018:9471583. https:\/\/doi.org\/10.1155\/2018\/9471583","journal-title":"Mediators Inflamm"},{"key":"2360_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00668-x","author":"R Wang","year":"2021","unstructured":"Wang R, Lin P, Sun H, Hu W (2021) Increased serum asprosin is correlated with diabetic nephropathy. Diabetol Metab Syndr. https:\/\/doi.org\/10.1186\/s13098-021-00668-x","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"2360_CR59","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1002\/iid3.947","volume":"11","author":"B Zhang","year":"2023","unstructured":"Zhang B, Lu J, Jiang Y, Feng Y (2023) Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling. Immun Inflamm Dis 11(8):e947. https:\/\/doi.org\/10.1002\/iid3.947","journal-title":"Immun Inflamm Dis"},{"key":"2360_CR60","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.tice.2020.101397","volume":"66","author":"N Kocaman","year":"2020","unstructured":"Kocaman N, Kuloglu T (2020) Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue Cell 66:101397. https:\/\/doi.org\/10.1016\/j.tice.2020.101397","journal-title":"Tissue Cell"},{"key":"2360_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41421-020-0152-4","volume":"6","author":"Y Liu","year":"2020","unstructured":"Liu Y, Long A, Chen L, Jia L, Wang Y (2020) The asprosin-OLFR734 module regulates appetitive behaviors. Cell Discov 6:19. https:\/\/doi.org\/10.1038\/s41421-020-0152-4","journal-title":"Cell Discov"},{"key":"2360_CR62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cmet.2022.02.012","volume":"34","author":"I Mishra","year":"2022","unstructured":"Mishra I, Xie WR, Bournat JC, He Y, Wang C, Silva ES et al (2022) Protein tyrosine phosphatase receptor delta serves as the orexigenic asprosin receptor. Cell Metab 34:549-63e8. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.012","journal-title":"Cell Metab"},{"issue":"5","key":"2360_CR63","doi-asserted-by":"publisher","first-page":"H1200","DOI":"10.1152\/ajpheart.00216.2018","volume":"315","author":"RA Dampney","year":"2018","unstructured":"Dampney RA, Michelini LC, Li DP, Pan HL (2018) Regulation of sympathetic vasomotor activity by the hypothalamic paraventricular nucleus in normotensive and hypertensive states. Am J Physiol Heart Circ Physiol 315(5):H1200\u2013H1214. https:\/\/doi.org\/10.1152\/ajpheart.00216.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2360_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012595","author":"XL Wang","year":"2022","unstructured":"Wang XL, Wang JX, Chen JL, Hao WY, Xu WZ, Xu ZQ et al (2022) Asprosin in the paraventricular nucleus induces sympathetic activation and pressor responses via cAMP-dependent ROS production. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232012595","journal-title":"Int J Mol Sci"},{"key":"2360_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41421-019-0122-x","volume":"5","author":"F Wei","year":"2019","unstructured":"Wei F, Long A, Wang Y (2019) The asprosin-OLFR734 hormonal signaling axis modulates male fertility. Cell Discov 5:55. https:\/\/doi.org\/10.1038\/s41421-019-0122-x","journal-title":"Cell Discov"},{"issue":"11","key":"2360_CR66","doi-asserted-by":"publisher","first-page":"e14579","DOI":"10.1111\/and.14579","volume":"54","author":"S Maurya","year":"2022","unstructured":"Maurya S, Krishna A, Lal B, Singh A (2022) Asprosin promotes steroidogenesis and spermatogenesis with improved glucose metabolism in adult mice testis. Andrologia 54(11):e14579. https:\/\/doi.org\/10.1111\/and.14579","journal-title":"Andrologia"},{"issue":"1","key":"2360_CR67","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1038\/s41598-023-31271-x","volume":"13","author":"P Sathoria","year":"2023","unstructured":"Sathoria P, Chuphal B, Rai U, Roy B (2023) Molecular cloning, characterization and 3D modelling of spotted snakehead fbn1 C-terminal region encoding asprosin and expression analysis of fbn1. Sci Rep 13(1):4470. https:\/\/doi.org\/10.1038\/s41598-023-31271-x","journal-title":"Sci Rep"},{"issue":"2","key":"2360_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/01443615.2020.1758926","volume":"41","author":"R Deniz","year":"2021","unstructured":"Deniz R, Yavuzkir S, Ugur K, Ustebay DU, Baykus Y, Ustebay S et al (2021) Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol 41(2):279\u2013284. https:\/\/doi.org\/10.1080\/01443615.2020.1758926","journal-title":"J Obstet Gynaecol"},{"key":"2360_CR69","doi-asserted-by":"publisher","first-page":"7375294","DOI":"10.1155\/2018\/7375294","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, Liao M, Shen R, Zhang L, Hu H, Wu J et al (2018) Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm 2018:7375294. https:\/\/doi.org\/10.1155\/2018\/7375294","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2360_CR70","doi-asserted-by":"publisher","first-page":"2152790","DOI":"10.1080\/09513590.2022.2152790","volume":"39","author":"FR Perez-Lopez","year":"2023","unstructured":"Perez-Lopez FR, Lopez-Baena MT, Perez-Roncero GR, Chedraui P, Varikasuvu SR, Garcia-Alfaro P (2023) Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 39(1):2152790. https:\/\/doi.org\/10.1080\/09513590.2022.2152790","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"2360_CR71","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1038\/s41598-019-42061-9","volume":"9","author":"CL Chang","year":"2019","unstructured":"Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK (2019) The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep 9(1):6447. https:\/\/doi.org\/10.1038\/s41598-019-42061-9","journal-title":"Sci Rep"},{"key":"2360_CR72","doi-asserted-by":"publisher","first-page":"114036","DOI":"10.1016\/j.ygcen.2022.114036","volume":"323\u2013324","author":"S Maurya","year":"2022","unstructured":"Maurya S, Singh A (2022) Asprosin modulates testicular functions during ageing in mice. Gen Comp Endocrinol 323\u2013324:114036. https:\/\/doi.org\/10.1016\/j.ygcen.2022.114036","journal-title":"Gen Comp Endocrinol"},{"key":"2360_CR73","doi-asserted-by":"publisher","first-page":"111451","DOI":"10.1016\/j.mce.2021.111451","volume":"538","author":"T Keskin","year":"2021","unstructured":"Keskin T, Erden Y, Tekin S (2021) Intracerebroventricular asprosin administration strongly stimulates hypothalamic-pituitary-testicular axis in rats. Mol Cell Endocrinol 538:111451. https:\/\/doi.org\/10.1016\/j.mce.2021.111451","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2360_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/JME-20-0218","volume":"66","author":"ERS Maylem","year":"2021","unstructured":"Maylem ERS, Spicer LJ, Batalha I, Schutz LF (2021) Discovery of a possible role of asprosin in ovarian follicular function. J Mol Endocrinol 66(1):35\u201344. https:\/\/doi.org\/10.1530\/JME-20-0218","journal-title":"J Mol Endocrinol"},{"key":"2360_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.theriogenology.2021.11.004","volume":"178","author":"ERS Maylem","year":"2022","unstructured":"Maylem ERS, Spicer LJ, Atabay EP, Atabay EC, Batalha I, Schutz LF (2022) A potential role of fibrillin-1 (FBN1) mRNA and asprosin in follicular development in water buffalo. Theriogenology 178:67\u201372. https:\/\/doi.org\/10.1016\/j.theriogenology.2021.11.004","journal-title":"Theriogenology"},{"key":"2360_CR76","doi-asserted-by":"publisher","first-page":"111890","DOI":"10.1016\/j.mce.2023.111890","volume":"565","author":"IM Batalha","year":"2023","unstructured":"Batalha IM, Maylem ERS, Spicer LJ, Pena Bello CA, Archilia EC, Schutz LF (2023) Effects of asprosin on estradiol and progesterone secretion and proliferation of bovine granulosa cells. Mol Cell Endocrinol 565:111890. https:\/\/doi.org\/10.1016\/j.mce.2023.111890","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"2360_CR77","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ajem.2017.12.032","volume":"36","author":"AC Acara","year":"2018","unstructured":"Acara AC, Bolatkale M, Kiziloglu I, Ibisoglu E, Can C (2018) A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med 36(8):1504\u20131505. https:\/\/doi.org\/10.1016\/j.ajem.2017.12.032","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2360_CR78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12944-021-01514-9","volume":"20","author":"N Moradi","year":"2021","unstructured":"Moradi N, Fouani FZ, Vatannejad A, Bakhti Arani A, Shahrzad S, Fadaei R (2021) Serum levels of asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study. Lipids Health Dis 20(1):88. https:\/\/doi.org\/10.1186\/s12944-021-01514-9","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2360_CR79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12872-020-01680-1","volume":"20","author":"MS Wen","year":"2020","unstructured":"Wen MS, Wang CY, Yeh JK, Chen CC, Tsai ML, Ho MY et al (2020) The role of asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord 20(1):402. https:\/\/doi.org\/10.1186\/s12872-020-01680-1","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2360_CR80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-022-01457-0","volume":"21","author":"M You","year":"2022","unstructured":"You M, Liu Y, Wang B, Li L, Zhang H, He H et al (2022) Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease. Cardiovasc Diabetol 21(1):25. https:\/\/doi.org\/10.1186\/s12933-022-01457-0","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2360_CR81","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/CIRCRESAHA.121.320694","volume":"130","author":"G Liang","year":"2022","unstructured":"Liang G, Wang S, Shao J, Jin YJ, Xu L, Yan Y et al (2022) Tenascin-X mediates flow-induced suppression of EndMT and atherosclerosis. Circ Res 130(11):1647\u20131659. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.320694","journal-title":"Circ Res"},{"issue":"9","key":"2360_CR82","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1139\/apnm-2020-0005","volume":"45","author":"JF Halling","year":"2020","unstructured":"Halling JF, Pilegaard H (2020) PGC-1alpha-mediated regulation of mitochondrial function and physiological implications. Appl Physiol Nutr Metab 45(9):927\u2013936. https:\/\/doi.org\/10.1139\/apnm-2020-0005","journal-title":"Appl Physiol Nutr Metab"},{"issue":"11","key":"2360_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040369","volume":"4","author":"CJ Lelliott","year":"2006","unstructured":"Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M et al (2006) Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 4(11):e369. https:\/\/doi.org\/10.1371\/journal.pbio.0040369","journal-title":"PLoS Biol"},{"key":"2360_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050666","author":"JR Ko","year":"2019","unstructured":"Ko JR, Seo DY, Kim TN, Park SH, Kwak HB, Ko KS et al (2019) Aerobic exercise training decreases hepatic asprosin in diabetic rats. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8050666","journal-title":"J Clin Med"},{"issue":"1","key":"2360_CR85","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12967-022-03542-0","volume":"20","author":"J Zou","year":"2022","unstructured":"Zou J, Xu C, Zhao ZW, Yin SH, Wang G (2022) Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38\/Elk-1 pathway. J Transl Med 20(1):337. https:\/\/doi.org\/10.1186\/s12967-022-03542-0","journal-title":"J Transl Med"},{"issue":"2","key":"2360_CR86","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R (1999) Atherosclerosis\u2013an inflammatory disease. N Engl J Med 340(2):115\u2013126. https:\/\/doi.org\/10.1056\/NEJM199901143400207","journal-title":"N Engl J Med"},{"key":"2360_CR87","doi-asserted-by":"publisher","first-page":"116554","DOI":"10.1016\/j.lfs.2019.116554","volume":"231","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Tan Y, Zhu L, Zhang B, Feng P, Gao E et al (2019) Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1\/2-SOD2 pathway. Life Sci 231:116554. https:\/\/doi.org\/10.1016\/j.lfs.2019.116554","journal-title":"Life Sci"},{"issue":"7","key":"2360_CR88","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1007\/s11033-021-06551-2","volume":"48","author":"G Goodarzi","year":"2021","unstructured":"Goodarzi G, Setayesh L, Fadaei R, Khamseh ME, Aliakbari F, Hosseini J et al (2021) Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy. Mol Biol Rep 48(7):5443\u20135450. https:\/\/doi.org\/10.1007\/s11033-021-06551-2","journal-title":"Mol Biol Rep"},{"issue":"2","key":"2360_CR89","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/jdi.13148","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Jiang H, Ma X, Wu H (2020) Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig 11(2):349\u2013355. https:\/\/doi.org\/10.1111\/jdi.13148","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2360_CR90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/JOE-20-0131","volume":"247","author":"M Chittezhath","year":"2020","unstructured":"Chittezhath M, Wai CMM, Tay VSY, Chua M, Langley SR, Ali Y (2020) TLR4 signals through islet macrophages to alter cytokine secretion during diabetes. J Endocrinol 247(1):87. https:\/\/doi.org\/10.1530\/JOE-20-0131","journal-title":"J Endocrinol"},{"issue":"8","key":"2360_CR91","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00125-014-3249-1","volume":"57","author":"D Nackiewicz","year":"2014","unstructured":"Nackiewicz D, Dan M, He W, Kim R, Salmi A, Rutti S et al (2014) TLR2\/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6. Diabetologia 57(8):1645\u20131654. https:\/\/doi.org\/10.1007\/s00125-014-3249-1","journal-title":"Diabetologia"},{"key":"2360_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030706","author":"JHM Yung","year":"2020","unstructured":"Yung JHM, Giacca A (2020) Role of c-Jun N-terminal Kinase (JNK) in obesity and type 2 diabetes. Cells. https:\/\/doi.org\/10.3390\/cells9030706","journal-title":"Cells"},{"key":"2360_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010227","author":"K Shabir","year":"2022","unstructured":"Shabir K, Gharanei S, Orton S, Patel V, Chauhan P, Karteris E et al (2022) Asprosin exerts pro-inflammatory effects in THP-1 macrophages mediated via the toll-like receptor 4 (TLR4) pathway. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010227","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2360_CR94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jcp.29835","volume":"236","author":"R Wang","year":"2021","unstructured":"Wang R, Hu W (2021) Asprosin promotes beta-cell apoptosis by inhibiting the autophagy of beta-cell via AMPK-mTOR pathway. J Cell Physiol 236(1):215\u2013221. https:\/\/doi.org\/10.1002\/jcp.29835","journal-title":"J Cell Physiol"},{"issue":"2","key":"2360_CR95","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"3","key":"2360_CR96","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/cphy.c190029","volume":"10","author":"KE Merz","year":"2020","unstructured":"Merz KE, Thurmond DC (2020) Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol 10(3):785\u2013809. https:\/\/doi.org\/10.1002\/cphy.c190029","journal-title":"Compr Physiol"},{"issue":"S2","key":"2360_CR97","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.2337\/dc09-S302","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(S2):S157\u2013S163. https:\/\/doi.org\/10.2337\/dc09-S302","journal-title":"Diabetes Care"},{"issue":"6","key":"2360_CR98","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1002\/jcp.27603","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A (2019) Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol 234(6):8152\u20138161. https:\/\/doi.org\/10.1002\/jcp.27603","journal-title":"J Cell Physiol"},{"issue":"11","key":"2360_CR99","doi-asserted-by":"publisher","first-page":"20888","DOI":"10.1002\/jcp.28694","volume":"234","author":"TW Jung","year":"2019","unstructured":"Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U et al (2019) Asprosin attenuates insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol 234(11):20888\u201320899. https:\/\/doi.org\/10.1002\/jcp.28694","journal-title":"J Cell Physiol"},{"key":"2360_CR100","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3389\/fphys.2018.01782","volume":"9","author":"M Wiecek","year":"2018","unstructured":"Wiecek M, Szymura J, Maciejczyk M, Kantorowicz M, Szygula Z (2018) Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines-a comparison between sexes. Front Physiol 9:1782. https:\/\/doi.org\/10.3389\/fphys.2018.01782","journal-title":"Front Physiol"},{"issue":"8","key":"2360_CR101","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s11255-020-02509-8","volume":"52","author":"H Zhang","year":"2020","unstructured":"Zhang H, Hu W, Zhang G (2020) Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol 52(8):1517\u20131522. https:\/\/doi.org\/10.1007\/s11255-020-02509-8","journal-title":"Int Urol Nephrol"},{"key":"2360_CR102","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.2147\/DMSO.S283413","volume":"13","author":"X Deng","year":"2020","unstructured":"Deng X, Zhao L, Guo C, Yang L, Wang D, Li Y et al (2020) Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes. Diabetes Metab Syndr Obes 13:4341\u20134351. https:\/\/doi.org\/10.2147\/DMSO.S283413","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02360-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:09:12Z","timestamp":1721786952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02360-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":102,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2360"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02360-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}